{"id":"https://openalex.org/W4288037069","doi":"https://doi.org/10.1093/ijnp/pyac041","title":"5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an Fmr1-Targeted Transgenic Male Rat Model of Fragile X Syndrome","display_name":"5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an Fmr1-Targeted Transgenic Male Rat Model of Fragile X Syndrome","publication_year":2022,"publication_date":"2022-07-26","ids":{"openalex":"https://openalex.org/W4288037069","doi":"https://doi.org/10.1093/ijnp/pyac041","pmid":"https://pubmed.ncbi.nlm.nih.gov/35882205","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9515134"},"language":"en","primary_location":{"id":"doi:10.1093/ijnp/pyac041","doi":"https://doi.org/10.1093/ijnp/pyac041","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ijnp/pyac041","pdf_url":"https://academic.oup.com/ijnp/article-pdf/25/9/786/46107220/pyac041.pdf","source":{"id":"https://openalex.org/S199972112","display_name":"The International Journal of Neuropsychopharmacology","issn_l":"1461-1457","issn":["1461-1457","1469-5111"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311647","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/P4310311647"],"host_organization_lineage_names":["University of Oxford"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Neuropsychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/ijnp/article-pdf/25/9/786/46107220/pyac041.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089779113","display_name":"Mayako Yamazaki","orcid":"https://orcid.org/0000-0002-1654-1851","observed_orcids":["https://orcid.org/0000-0002-1654-1851"]},"institutions":[{"id":"https://openalex.org/I142395110","display_name":"Astellas Pharma (Japan)","ror":"https://ror.org/01cjash87","country_code":"JP","type":"company","lineage":["https://openalex.org/I142395110"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Mayako Yamazaki","raw_affiliation_strings":["Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"],"raw_orcid":"https://orcid.org/0000-0002-1654-1851","affiliations":[{"raw_affiliation_string":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan","institution_ids":["https://openalex.org/I142395110"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032369497","display_name":"Takatomo Arai","orcid":"https://orcid.org/0009-0007-6672-1125","observed_orcids":["https://orcid.org/0009-0007-6672-1125"]},"institutions":[{"id":"https://openalex.org/I142395110","display_name":"Astellas Pharma (Japan)","ror":"https://ror.org/01cjash87","country_code":"JP","type":"company","lineage":["https://openalex.org/I142395110"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takatomo Arai","raw_affiliation_strings":["Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan","institution_ids":["https://openalex.org/I142395110"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066493166","display_name":"Junko Yarimizu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142395110","display_name":"Astellas Pharma (Japan)","ror":"https://ror.org/01cjash87","country_code":"JP","type":"company","lineage":["https://openalex.org/I142395110"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Junko Yarimizu","raw_affiliation_strings":["Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan","institution_ids":["https://openalex.org/I142395110"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075432487","display_name":"Mitsuyuki Matsumoto","orcid":"https://orcid.org/0000-0002-1172-2354","observed_orcids":["https://orcid.org/0000-0002-1172-2354"]},"institutions":[{"id":"https://openalex.org/I142395110","display_name":"Astellas Pharma (Japan)","ror":"https://ror.org/01cjash87","country_code":"JP","type":"company","lineage":["https://openalex.org/I142395110"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mitsuyuki Matsumoto","raw_affiliation_strings":["Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan","Neuroscience, La Jolla Laboratory, Astellas Research Institute of America LLC , San Diego, CA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan","institution_ids":["https://openalex.org/I142395110"]},{"raw_affiliation_string":"Neuroscience, La Jolla Laboratory, Astellas Research Institute of America LLC , San Diego, CA , USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5089779113"],"corresponding_institution_ids":["https://openalex.org/I142395110"],"apc_list":{"value":1945,"currency":"GBP","value_usd":2406},"apc_paid":{"value":1945,"currency":"GBP","value_usd":2406},"fwci":0.8565,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.6645048,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"25","issue":"9","first_page":"786","last_page":"793"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11772","display_name":"Genetics and Neurodevelopmental Disorders","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11772","display_name":"Genetics and Neurodevelopmental Disorders","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10106","display_name":"Autism Spectrum Disorder Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fragile-x-syndrome","display_name":"fragile X syndrome","score":0.8529999852180481},{"id":"https://openalex.org/keywords/hyperactivity","display_name":"hyperactivity","score":0.9459999799728394},{"id":"https://openalex.org/keywords/prepulse-inhibition","display_name":"prepulse inhibition","score":0.9929999709129333},{"id":"https://openalex.org/keywords/sensorimotor-gating","display_name":"sensorimotor gating","score":0.875},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.8190000057220459},{"id":"https://openalex.org/keywords/novel-object-recognition","display_name":"novel object recognition","score":0.9369999766349792},{"id":"https://openalex.org/keywords/drug-candidates","display_name":"drug candidates","score":0.42500001192092896}],"concepts":[{"id":"https://openalex.org/C2777630245","wikidata":"https://www.wikidata.org/wiki/Q221472","display_name":"Fragile X syndrome","level":2,"score":0.8715275526046753},{"id":"https://openalex.org/C2779063550","wikidata":"https://www.wikidata.org/wiki/Q905435","display_name":"FMR1","level":4,"score":0.8573280572891235},{"id":"https://openalex.org/C141421786","wikidata":"https://www.wikidata.org/wiki/Q1128897","display_name":"Prepulse inhibition","level":3,"score":0.8566442131996155},{"id":"https://openalex.org/C2779705967","wikidata":"https://www.wikidata.org/wiki/Q2271368","display_name":"Sensory gating","level":3,"score":0.6255808472633362},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5213083624839783},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.48765671253204346},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40223434567451477},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.3449251055717468},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3395138382911682},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32753387093544006},{"id":"https://openalex.org/C194544171","wikidata":"https://www.wikidata.org/wiki/Q21105679","display_name":"Gating","level":2,"score":0.20967739820480347},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.206509530544281},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.20231586694717407},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.07810696959495544},{"id":"https://openalex.org/C3020422209","wikidata":"https://www.wikidata.org/wiki/Q221472","display_name":"Fragile x","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005600","descriptor_name":"Fragile X Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005600","descriptor_name":"Fragile X Syndrome","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D006146","descriptor_name":"Guanidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008569","descriptor_name":"Memory Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008694","descriptor_name":"Methamphetamine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011985","descriptor_name":"Receptors, Serotonin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012601","descriptor_name":"Scopolamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012701","descriptor_name":"Serotonin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018345","descriptor_name":"Mice, Knockout","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051860","descriptor_name":"Fragile X Messenger Ribonucleoprotein 1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D051860","descriptor_name":"Fragile X Messenger Ribonucleoprotein 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D055647","descriptor_name":"Rats, Transgenic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1093/ijnp/pyac041","doi":"https://doi.org/10.1093/ijnp/pyac041","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ijnp/pyac041","pdf_url":"https://academic.oup.com/ijnp/article-pdf/25/9/786/46107220/pyac041.pdf","source":{"id":"https://openalex.org/S199972112","display_name":"The International Journal of Neuropsychopharmacology","issn_l":"1461-1457","issn":["1461-1457","1469-5111"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311647","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/P4310311647"],"host_organization_lineage_names":["University of Oxford"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Neuropsychopharmacology","raw_type":"journal-article"},{"id":"pmid:35882205","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35882205","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The international journal of neuropsychopharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9515134","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9515134/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int J Neuropsychopharmacol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/ijnp/pyac041","doi":"https://doi.org/10.1093/ijnp/pyac041","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ijnp/pyac041","pdf_url":"https://academic.oup.com/ijnp/article-pdf/25/9/786/46107220/pyac041.pdf","source":{"id":"https://openalex.org/S199972112","display_name":"The International Journal of Neuropsychopharmacology","issn_l":"1461-1457","issn":["1461-1457","1469-5111"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311647","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/P4310311647"],"host_organization_lineage_names":["University of Oxford"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Neuropsychopharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4288037069.pdf","grobid_xml":"https://content.openalex.org/works/W4288037069.grobid-xml"},"referenced_works_count":41,"referenced_works":["https://openalex.org/W275670288","https://openalex.org/W1579518684","https://openalex.org/W1649075337","https://openalex.org/W1975351746","https://openalex.org/W1984618862","https://openalex.org/W1986859027","https://openalex.org/W1990388039","https://openalex.org/W1990414759","https://openalex.org/W1992048305","https://openalex.org/W1997975229","https://openalex.org/W2003659920","https://openalex.org/W2014102314","https://openalex.org/W2018703700","https://openalex.org/W2027437909","https://openalex.org/W2029277771","https://openalex.org/W2041052694","https://openalex.org/W2046570248","https://openalex.org/W2058424007","https://openalex.org/W2060884332","https://openalex.org/W2065733295","https://openalex.org/W2068721994","https://openalex.org/W2073113115","https://openalex.org/W2073347350","https://openalex.org/W2090260786","https://openalex.org/W2097759310","https://openalex.org/W2100770813","https://openalex.org/W2115306800","https://openalex.org/W2130497862","https://openalex.org/W2135278071","https://openalex.org/W2149919973","https://openalex.org/W2164962682","https://openalex.org/W2272305265","https://openalex.org/W2309289911","https://openalex.org/W2502065076","https://openalex.org/W2522831505","https://openalex.org/W2589935846","https://openalex.org/W2759433538","https://openalex.org/W2790818339","https://openalex.org/W2791211198","https://openalex.org/W2902667916","https://openalex.org/W3096900792"],"related_works":["https://openalex.org/W2619089706","https://openalex.org/W2103709346","https://openalex.org/W2094993063","https://openalex.org/W3168923313","https://openalex.org/W7140029258","https://openalex.org/W2162893002","https://openalex.org/W3007078750","https://openalex.org/W2127143111","https://openalex.org/W2045611288","https://openalex.org/W3169345011"],"abstract_inverted_index":{"BACKGROUND:":[0],"Fragile":[1],"X":[2],"syndrome":[3],"(FXS)":[4],"is":[5,184],"a":[6,11,51,102,185],"genetic":[7],"condition":[8],"that":[9,49,86],"causes":[10],"range":[12],"of":[13,82,105,112,116,122],"developmental":[14],"problems,":[15],"including":[16],"intellectual":[17],"disability,":[18],"aggressive":[19],"behavior,":[20],"anxiety,":[21],"abnormal":[22,120,153],"sensory":[23,154,169],"processing,":[24],"and":[25,71,75,133,157,166],"cognitive":[26,77,158,180],"impairment.":[27,159,181],"Despite":[28],"intensive":[29],"preclinical":[30,103],"research":[31],"in":[32,63,68,79,96,141],"Fmr1-targeted":[33,98],"transgenic":[34,99],"mice,":[35,64],"an":[36],"effective":[37,90],"treatment":[38],"for":[39,91,189],"FXS":[40],"has":[41],"yet":[42],"to":[43,195],"be":[44,89],"developed.":[45],"We":[46,84,108],"previously":[47],"demonstrated":[48],"ASP5736,":[50],"5-Hydroxytryptamine":[52],"(serotonin)":[53],"receptor":[54,56],"5A":[55],"antagonist,":[57],"ameliorated":[58,167],"scopolamine-induced":[59],"working":[60],"memory":[61,66],"deficits":[62,95,172],"reference":[65],"impairment":[67,78],"aged":[69],"rats,":[70],"methamphetamine-induced":[72],"positive":[73],"symptoms":[74],"phencyclidine-induced":[76],"animal":[80],"models":[81],"schizophrenia.":[83],"hypothesized":[85],"ASP5736":[87,117,160,175,183],"may":[88],"ameliorating":[92],"similar":[93],"behavior":[94,121],"male":[97],"rats":[100,147],"as":[101],"model":[104],"FXS.":[106,190],"METHODS:":[107],"evaluated":[109],"the":[110,119,134,164,168],"effect":[111],"acute":[113],"oral":[114],"administration":[115],"on":[118],"hyperactivity":[123,165],"(0.01,":[124,129],"0.1":[125,131],"mg/kg),":[126,132],"prepulse":[127],"inhibition":[128],"0.03,":[130],"novel":[135],"object":[136],"recognition":[137],"task":[138],"(0.1":[139,161],"mg/kg)":[140,162,177],"Frmr1-knockout":[142],"(KO)":[143],"rats.":[144],"RESULTS:":[145],"Fmr1-KO":[146],"showed":[148],"body":[149],"weight":[150],"gain,":[151],"hyperactivity,":[152],"motor":[155,170],"gating,":[156],"reversed":[163],"gating":[171],"(0.03-0.1":[173],"mg/kg).":[174],"(0.01":[176],"also":[178],"improved":[179],"CONCLUSIONS:":[182],"potential":[186],"drug":[187],"candidate":[188],"Further":[191],"studies":[192],"are":[193],"needed":[194],"confirm":[196],"its":[197],"clinical":[198],"efficacy.":[199]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2022-07-27T00:00:00"}